+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A novel strategy for NQO1 Hquinone oxidoreductase, EC 16992 mediated therapy of bladder cancer based on the pharmacological properties of EO9



A novel strategy for NQO1 Hquinone oxidoreductase, EC 16992 mediated therapy of bladder cancer based on the pharmacological properties of EO9



British Journal of Cancer 85(8): 1137-1146, 19 October



The indolequinone EO9 demonstrated good preclinical activity but failed to show clinical efficacy against a range of tumours following intravenous drug administration. A significant factor in EO9's failure in the clinic has been attributed to its rapid pharmacokinetic elimination resulting in poor drug delivery to tumours. Intravesical administration of EO9 would circumvent the problem of drug delivery to tumours and the principal objective of this study is to determine whether or not bladder tumours have elevated levels of the enzyme NQO1 (NAD(P)H:quinone oxidoreductase) which plays a key role in activating EO9 under aerobic conditions. Elevated NQO1 levels in human bladder tumour tissue exist in a subset of patients as measured by both immunohistochemical and enzymatic assays. In a panel of human tumour cell lines, EO9 is selectively toxic towards NQO1 rich cell lines under aerobic conditions and potency can be enhanced by reducing extracellular pH. These studies suggest that a subset of bladder cancer patients exist whose tumours possess the appropriate biochemical machinery required to activate EO9. Administration of EO9 in an acidic vehicle could be employed to reduce possible systemic toxicity as any drug absorbed into the blood stream would become relatively inactive due to an increase in pH.

(PDF emailed within 1 workday: $29.90)

Accession: 034312270

Download citation: RISBibTeXText


Related references

A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. British Journal of Cancer 85(8): 1137-1146, 2001

Immunodetection of GLUT-1 and NQO1 Hquinone oxidoreductase in superficial bladder cancer. British Journal of Cancer 88(Supplement 1): S30, 2003

Inhibition of DT-diaphorase HQuinone oxidoreductase, EC 16992 by 5,6-dimethylxanthenone-4-acetic acid. Biochemical Pharmacology 58(2): 303-310, July 15, 1999

The NQO1*2 polymorphism in NAD Hquinone oxidoreductase 1 targets the protein for proteasomal degradation. Proceedings of the American Association for Cancer Research Annual Meeting (41): 35, 2000

Heat shock increases expression of NAD(P)H:quinone oxidoreductase (NQO1), mediator of beta-lapachone cytotoxicity, by increasing NQO1 gene activity and via Hsp70-mediated stabilisation of NQO1 protein. International Journal of Hyperthermia 25(6): 477-487, 2010

Metabolism of indolequinone antitumor agents by human NAD- Hquinone oxidoreductase and inactivation of NQO1 by carbamoyloxymethyl-substituted indolequinones. Proceedings of the American Association for Cancer Research Annual Meeting 39: 224, 1998

Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. Biochemistry 46(20): 5941-5950, 2007

Catalytic properties of NAD HQuinone oxidoreductase-2 , a dihydronicotinamide riboside dependent oxidoreductase. Archives of Biochemistry & Biophysics 347(2): 221-228, Nov 15, 1997

Affinity-based small fluorescent probe for NAD(P)H:quinone oxidoreductase 1 (NQO1). Design, synthesis and pharmacological evaluation. European Journal of Medicinal Chemistry 127: 828-839, 2016

Genotyping of NAD Hquinone oxidoreductase in a panel of human tumor xenografts Relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo. Biochemical Pharmacology 62(10): 1371-1377, 15 November, 2001

Overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones. Life Sciences 145: 57-65, 2016

A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. British Journal of Cancer 74(6): 995-996, 1996

Evidence for NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated quinone-dependent redox cycling via plasma membrane electron transport: A sensitive cellular assay for NQO1. Free Radical Biology and Medicine 48(3): 421-429, 2010

NADPHQuinone oxidoreductase 1 NQO1 protects bladder epithelium against painful bladder syndrome in mice. 2012

NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells. Toxicology Letters 262: 1-11, 2016